Ennis Zaitoon, MD
Internal Medicine · Corona, CANPI 1235307141
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,550 of the $6,676 with a category attached, or 68.2%. Lilly USA, LLC accounts for 74.0% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $4,932, 5.7 times the $861 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $59.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$5K
- Novo Nordisk$574
- Amgen$264
- Boehringer Ingelheim$95
- Sunovion Pharmaceuticals Inc.$77
- Eisai Inc.$76
- plus $653 from 22 others
What the payments were for
- Speaking & faculty fees$4,55068%
- Travel & lodging$130%
- Food & beverage$2,08131%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $4,938 |
| Novo Nordisk | 28 | $574 |
| Amgen | 15 | $264 |
| Boehringer Ingelheim | 6 | $95 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Eisai Inc. | 5 | $76 |
| GSK | 3 | $68 |
| Pfizer | 4 | $58 |
| Bayer | 2 | $49 |
| Astellas Pharma US Inc | 2 | $45 |
| AstraZeneca | 3 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Nalpropion Pharmaceuticals LLC | 3 | $39 |
| Exact Sciences | 2 | $38 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| Abbott | 1 | $26 |
| Edwards Lifesciences | 1 | $23 |
| Urovant Sciences Inc | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Intra-sana Laboratories | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,676 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $102,464 |
| JardianceEmpagliflozin | 54 | $58,111 |
| MounjaroTirzepatide | 37 | $48,216 |
| JanuviaSitagliptin Phosphate | 31 | $42,892 |
| TrulicityDulaglutide | 35 | $41,295 |
| EliquisApixaban | 34 | $29,577 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $21,240 |
| XareltoRivaroxaban | 18 | $20,821 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $15,835 |
| LinzessLinaclotide | 15 | $9,217 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $7,292 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $5,037 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,081 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 36 | $2,786 |
| Atorvastatin Calcium | 285 | $2,749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $574 | $102,46476 claims |
| Lilly USA, LLCMounjaro, Trulicity | $4,938 | $89,51172 claims |
| Boehringer IngelheimJardiance | $95 | $58,11154 claims |
| MerckJanuvia | $11 | $42,89231 claims |
| PfizerEliquis | $58 | $29,57734 claims |
| Johnson & JohnsonXarelto | $32 | $20,82118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Corona
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.